These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Ocular pharmacokinetics of acyclovir amino acid ester prodrugs in the anterior chamber: evaluation of their utility in treating ocular HSV infections. Katragadda S; Gunda S; Hariharan S; Mitra AK Int J Pharm; 2008 Jul; 359(1-2):15-24. PubMed ID: 18472234 [TBL] [Abstract][Full Text] [Related]
3. Amino acid prodrugs of acyclovir as possible antiviral agents against ocular HSV-1 infections: interactions with the neutral and cationic amino acid transporter on the corneal epithelium. Anand BS; Katragadda S; Nashed YE; Mitra AK Curr Eye Res; 2004; 29(2-3):153-66. PubMed ID: 15512962 [TBL] [Abstract][Full Text] [Related]
4. In vivo ocular pharmacokinetics of acyclovir dipeptide ester prodrugs by microdialysis in rabbits. Anand BS; Katragadda S; Gunda S; Mitra AK Mol Pharm; 2006; 3(4):431-40. PubMed ID: 16889437 [TBL] [Abstract][Full Text] [Related]
5. Synergistic penetration of ethosomes and lipophilic prodrug on the transdermal delivery of acyclovir. Zhou Y; Wei YH; Zhang GQ; Wu XA Arch Pharm Res; 2010 Apr; 33(4):567-74. PubMed ID: 20422366 [TBL] [Abstract][Full Text] [Related]
6. Influence of a niosomal formulation on the oral bioavailability of acyclovir in rabbits. Attia IA; El-Gizawy SA; Fouda MA; Donia AM AAPS PharmSciTech; 2007 Dec; 8(4):E106. PubMed ID: 18181527 [TBL] [Abstract][Full Text] [Related]
9. Interaction of acyclovir and its squalenoyl-acyclovir prodrug with DMPC in monolayers at the air/water interface. Sarpietro MG; Rocco F; Micieli D; Ottimo S; Ceruti M; Castelli F Int J Pharm; 2010 Aug; 395(1-2):167-73. PubMed ID: 20635474 [TBL] [Abstract][Full Text] [Related]
10. Novel dipeptide prodrugs of acyclovir for ocular herpes infections: Bioreversion, antiviral activity and transport across rabbit cornea. Anand B; Nashed Y; Mitra A Curr Eye Res; 2003; 26(3-4):151-63. PubMed ID: 12815543 [TBL] [Abstract][Full Text] [Related]
11. Self-assembled drug delivery systems. 1. Properties and in vitro/in vivo behavior of acyclovir self-assembled nanoparticles (SAN). Jin Y; Tong L; Ai P; Li M; Hou X Int J Pharm; 2006 Feb; 309(1-2):199-207. PubMed ID: 16377106 [TBL] [Abstract][Full Text] [Related]
12. Conjugation of squalene to acyclovir improves the affinity for biomembrane models. Sarpietro MG; Micieli D; Rocco F; Ceruti M; Castelli F Int J Pharm; 2009 Dec; 382(1-2):73-9. PubMed ID: 19686827 [TBL] [Abstract][Full Text] [Related]
13. Development and characterization of sponge-like acyclovir ocular minitablets. Refai H; Tag R Drug Deliv; 2011 Jan; 18(1):38-45. PubMed ID: 20804440 [TBL] [Abstract][Full Text] [Related]
14. Ocular penetration of acyclovir and its peptide prodrugs valacyclovir and val-valacyclovir following systemic administration in rabbits: An evaluation using ocular microdialysis and LC-MS. Dias C; Nashed Y; Atluri H; Mitra A Curr Eye Res; 2002 Oct; 25(4):243-52. PubMed ID: 12658558 [TBL] [Abstract][Full Text] [Related]
15. Transcorneal permeation of L- and D-aspartate ester prodrugs of acyclovir: delineation of passive diffusion versus transporter involvement. Majumdar S; Hingorani T; Srirangam R; Gadepalli RS; Rimoldi JM; Repka MA Pharm Res; 2009 May; 26(5):1261-9. PubMed ID: 18839288 [TBL] [Abstract][Full Text] [Related]
16. Aqueous nanomicellar formulation for topical delivery of biotinylated lipid prodrug of acyclovir: formulation development and ocular biocompatibility. Vadlapudi AD; Cholkar K; Vadlapatla RK; Mitra AK J Ocul Pharmacol Ther; 2014 Feb; 30(1):49-58. PubMed ID: 24192229 [TBL] [Abstract][Full Text] [Related]
17. A new homodimer of aciclovir as a prodrug with increased solubility and antiviral activity. Brandi G; Rossi L; Schiavano GF; Millo E; Magnani M Int J Antimicrob Agents; 2009 Aug; 34(2):177-80. PubMed ID: 19394201 [TBL] [Abstract][Full Text] [Related]
18. Novel nanoparticles made from amphiphilic perfluoroalkyl alpha-cyclodextrin derivatives: preparation, characterization and application to the transport of acyclovir. Ghera BB; Perret F; Chevalier Y; Parrot-Lopez H Int J Pharm; 2009 Jun; 375(1-2):155-62. PubMed ID: 19481701 [TBL] [Abstract][Full Text] [Related]
19. Targeted lipid based drug conjugates: a novel strategy for drug delivery. Vadlapudi AD; Vadlapatla RK; Kwatra D; Earla R; Samanta SK; Pal D; Mitra AK Int J Pharm; 2012 Sep; 434(1-2):315-24. PubMed ID: 22692074 [TBL] [Abstract][Full Text] [Related]
20. In vivo characterisation of a novel water-soluble Cyclosporine A prodrug for the treatment of dry eye disease. Rodriguez-Aller M; Kaufmann B; Guillarme D; Stella C; Furrer P; Rudaz S; El Zaoui I; Valamanesh F; Di Tommaso C; Behar-Cohen F; Veuthey JL; Gurny R Eur J Pharm Biopharm; 2012 Apr; 80(3):544-52. PubMed ID: 22155591 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]